Back to top

Analyst Blog

Leading medical devices maker CR Bard (BCR - Analyst Report) achieved a milestone by submitting the final pre-market approval (PMA) module to the U.S. Food and Drug Administration (FDA) for its Lutonix Drug-Coated PTA Dilatation Catheter (DCB).

This new technology, which combines the advantages of angioplasty balloons and drug-releasing stents, is used for the treatment of peripheral arterial disease in superficial femoral (SFA) and popliteal arteries.

Bard acquired Lutonix in Dec 2011. Lutonix DCB is available for sale in Europe and some other nations. In the U.S., the company is conducting a pivotal Levant 2 investigational device exemption (IDE) clinical trial comparing the Lutonix drug-coated balloon to standard balloon angioplasty.

The Levant 2 study is the first IDE trial approved by the FDA. It analyzed 476 patients with diseased femoropopliteal leg arteries across 55 medical centers globally. Data from Levant 2 along with Levant 1 and the Levant Continued Access Safety Registry have been submitted to the FDA regulatory panel.

Our Take

Approval of the Lutonix balloons from the FDA will be a significant achievement for BCR’s vascular products portfolio. The market opportunity for this new technology is huge.

Demand for the novel drug-coated balloons have been increasing among doctors as this advanced technology is capable of treating diseased arteries without the requirement of a permanent implant. As per independent research, it is forecasted that the global peripheral vascular market for this technology might exceed $1 billion annually over the next decade.

However, we are aware of stiff competition from other players in the field. Medtronic, Inc. (MDT - Analyst Report) has already submitted its foremost PMA module to the FDA for its IN.PACT Admiral drug-eluting balloon.

Covidien plc (COV - Analyst Report), another medical technologies giant, acquired CV Ingenuity in Jan 2013 to access its key product – a DCB platform with a unique tunable rapid-release system. The product is still in the investigational phase.

CR Bard presently has a Zacks Rank #3 (Hold). However, Align Technology (ALGN - Analyst Report) is a better-ranked stock than BCR in the medical/dental supplies industry, carrying a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
PLANAR SYST… PLNR 4.44 +5.21%
BITAUTO HOL… BITA 81.71 +5.12%
CTPARTNERS… CTP 16.66 +4.26%
CHINA BIOLO… CBPO 47.91 +3.30%
MALLINCKROD… MNK 72.94 +2.85%